Casdin Capital 13F holdings, Q3 2018
Holdings as of September 30, 2018 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 34 US equity positions worth $814.4m in its Q3 2018 13F filing. The largest position was LOXO ONCOLOGY INC at 7.6% of the reported book, followed by 2655787D and MYOKARDIA INC. Against the Q2 2018 filing, it opened 4 new positions, added to 14 and reduced 3 among the top 34 holdings.
What did Casdin Capital own in Q3 2018? Top 34 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2018 |
|---|---|---|---|---|---|---|---|
| 1 | LOXO ONCOLOGY INC | 7.6% | $61.5m | 360,000 | 0% | held | |
| 2 | 2655787D BLUEPRINT MEDICINES CORP | 7.2% | $58.5m | 750,000 | 18% | added | |
| 3 | MYOKARDIA INC | 6.4% | $52.5m | 805,000 | 3% | added | |
| 4 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 5.5% | $44.7m | 579,776 | 59% | added |
| 5 | SG7 SAGE THERAPEUTICS INC | 5.4% | $44.1m | 312,000 | 25% | added | |
| 6 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 5.2% | $42.5m | 2,428,571 | 143% | added |
| 7 | FATE FATE THERAPEUTICS INC | Healthcare | 5.1% | $41.5m | 2,550,000 | -2% | reduced |
| 8 | INVITAE CORP | 4.9% | $40.2m | 2,400,000 | – | new | |
| 9 | BLUEBIRD BIO INC | 4.6% | $37.7m | 258,000 | 29% | added | |
| 10 | SPARK THERAPEUTICS INC | 4.5% | $36.8m | 675,000 | 46% | added | |
| 11 | CDXS CODEXIS INC | Healthcare | 4.3% | $34.7m | 2,025,000 | 0% | held |
| 12 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 4.2% | $33.9m | 2,000,000 | 43% | added |
| 13 | MAGENTA THERAPEUTICS INC | 3.3% | $27.0m | 2,250,818 | 11% | added | |
| 14 | ILMN ILLUMINA INC | Healthcare | 3.2% | $26.2m | 71,500 | 0% | held |
| 15 | GNMK GENMARK DIAGNOSTICS INC | 3.2% | $25.7m | 3,500,000 | 3% | added | |
| 16 | AUDENTES THERAPEUTICS INC | 3.0% | $24.7m | 625,000 | 39% | added | |
| 17 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.9% | $23.6m | 270,000 | 0% | held |
| 18 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 2.6% | $21.5m | 1,135,000 | 0% | held |
| 19 | GLOBAL BLOOD THERAPEUTICS IN | 2.1% | $16.7m | 440,000 | -8% | reduced | |
| 20 | EVH EVOLENT HEALTH INC | Healthcare | 1.9% | $15.6m | 550,000 | 0% | held |
| 21 | EDIT EDITAS MEDICINE INC | Healthcare | 1.8% | $14.6m | 460,000 | 158% | added |
| 22 | ONC BEIGENE LTD | Healthcare | 1.5% | $12.1m | 70,000 | 0% | held |
| 23 | 2JQ GRITSTONE ONCOLOGY INC | 1.3% | $10.3m | 720,586 | – | new | |
| 24 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.2% | $9.8m | 220,000 | 0% | held |
| 25 | CNST CONSTELLATION PHARMCETICLS I | 1.1% | $8.8m | 1,314,743 | – | new | |
| 26 | OSUR ORASURE TECHNOLOGIES INC | Healthcare | 1.0% | $8.1m | 525,000 | -18% | reduced |
| 27 | HOMOLOGY MEDICINES INC | 1.0% | $8.0m | 350,000 | 204% | added | |
| 28 | CLOVIS ONCOLOGY INC | 0.8% | $6.9m | 235,000 | 7% | added | |
| 29 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 0.8% | $6.5m | 40,000 | – | new |
| 30 | CDNA CAREDX INC | Healthcare | 0.7% | $5.8m | 200,000 | 0% | held |
| 31 | NEOG NEOGEN CORP | Healthcare | 0.6% | $4.6m | 65,000 | 0% | held |
| 32 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.5% | $3.8m | 207,500 | 0% | held |
| 33 | NEON THERAPEUTICS INC | 0.4% | $2.9m | 338,345 | 0% | held | |
| 34 | JOUNCE THERAPEUTICS INC | 0.3% | $2.4m | 375,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.